ATI RN
ATI Pharmacology Proctored Exam
1. A client has a new prescription for atenolol. Which of the following findings should the nurse instruct the client to monitor for as an adverse effect of this medication?
- A. Tachycardia
- B. Hypoglycemia
- C. Bradycardia
- D. Hypertension
Correct answer: C
Rationale: The correct answer is 'C: Bradycardia.' Atenolol, a beta-blocker, commonly causes bradycardia as an adverse effect. It works by slowing down the heart rate, which can lead to a decreased heart rate known as bradycardia. Monitoring for signs of bradycardia is essential to prevent any potential complications while on atenolol. Choices A, B, and D are incorrect because atenolol is not known to cause tachycardia, hypoglycemia, or hypertension as common adverse effects.
2. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?
- A. Hypertension
- B. Hypokalemia
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Corrected Rationale: Bevacizumab is known to potentially cause hypertension as a common adverse effect. The nurse should monitor the client's blood pressure regularly to detect and manage any elevations effectively. Choices B, C, and D are incorrect because bevacizumab is not typically associated with causing hypokalemia, hyperglycemia, or hypocalcemia. Therefore, monitoring for hypertension is the priority in this case.
3. A client has a new prescription for rituximab. Which of the following findings should the nurse instruct the client to report?
- A. Dizziness
- B. Fever
- C. Urinary frequency
- D. Dry mouth
Correct answer: B
Rationale: The correct answer is B: Fever. The nurse should instruct the client to report fever as it can be an indication of an infection, which is a potential complication of rituximab therapy. Monitoring for fever is crucial to detect early signs of infection and prevent complications. Dizziness (choice A), urinary frequency (choice C), and dry mouth (choice D) are not typically associated with rituximab therapy and are not the primary concerns that the nurse needs to address with the client.
4. A client is prescribed Propranolol for dysrhythmia. Which action should the nurse plan to take?
- A. Hold Propranolol if the client's apical pulse is greater than 100/min.
- B. Monitor the client's blood pressure after administering Propranolol.
- C. Assist the client when transitioning to a sitting or standing position after taking Propranolol.
- D. Monitor the client's potassium levels for signs of Propranolol toxicity.
Correct answer: C
Rationale: The correct action the nurse should plan to take when administering Propranolol to a client with dysrhythmia is to assist the client when transitioning to a sitting or standing position. Propranolol can cause orthostatic hypotension, leading to dizziness during position changes, so it is essential to help the client move slowly to prevent falls or injuries. Choices A, B, and D are incorrect because holding Propranolol based on pulse rate, monitoring blood pressure after administration, and monitoring potassium levels are not directly related to the common side effect of orthostatic hypotension associated with Propranolol.
5. A client is receiving heparin therapy. Which of the following laboratory values should the nurse monitor to evaluate the effectiveness of the therapy?
- A. PT
- B. aPTT
- C. INR
- D. Platelet count
Correct answer: B
Rationale: The corrected answer is B: aPTT. The activated partial thromboplastin time (aPTT) is the laboratory value used to monitor the effectiveness of heparin therapy. The aPTT should be maintained at 1.5 to 2 times the normal level to ensure therapeutic anticoagulation. Monitoring aPTT helps healthcare providers adjust heparin doses to achieve the desired anticoagulant effects and prevent complications such as bleeding or clotting. Choice A, PT (prothrombin time), is used to monitor warfarin therapy, not heparin. Choice C, INR (international normalized ratio), is also used to monitor warfarin therapy. Choice D, platelet count, is important for assessing the risk of bleeding, but it does not directly monitor the effectiveness of heparin therapy.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access